For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Sunao Manabe, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Junichi Onuma,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
https://www.daiichisankyo.com

Daiichi Sankyo Submits Supplemental Application in Japan for Approval of Partial Changes in Usage or Dosage for Anticoagulant Edoxaban

Tokyo, Japan (September 11, 2020) – Daiichi Sankyo Company Limited (hereinafter, Daiichi Sankyo) announced today that it submitted an supplemental application in Japan for an expanded approved usage or dosage for the anticoagulant, edoxaban(edoxaban tosilate hydrate), for elderly patients with non-valvular atrial fibrillation and high bleeding risk.

 

This application is based on results from the Japanese phase 3 clinical trial (ELDERCARE-AF Study) in 984 non-valvular atrial fibrillation patients of 80 years and above with a high bleeding risk and who are ineligible for other available anticoagulation therapies.

 

Daiichi Sankyo expects to contribute to the treatment of elderly patients with non-valvular atrial fibrillation by providing the new treatment option.